Minireviews
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 14, 2024; 30(14): 1982-1989
Published online Apr 14, 2024. doi: 10.3748/wjg.v30.i14.1982
Omics-based biomarkers as useful tools in metabolic dysfunction-associated steatotic liver disease clinical practice: How far are we?
Julieta Trinks, María F Mascardi, Adrián Gadano, Sebastián Marciano
Julieta Trinks, María F Mascardi, Sebastián Marciano, Instituto de Medicina Traslacional e Ingeniería Biomédica - Consejo Nacional de Investigaciones Científicas y Técnicas - Instituto Universitario del Hospital Italiano - Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires C1199ACL, Argentina
Julieta Trinks, María F Mascardi, Sebastián Marciano, Consejo Nacional de Investigaciones Científicas y Técnicas, Ciudad Autónoma de Buenos Aires C1425FQB, Argentina
Adrián Gadano, Sebastián Marciano, Liver Unit, Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires C1199DF, Argentina
Adrián Gadano, Sebastián Marciano, Department of Research, Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires C1199DF, Argentina
Author contributions: Trinks J, Mascardi MF, and Marciano S wrote the paper; Trinks J and Mascardi MF performed the literature search and data analysis; Gadano A contributed to the review and editing of the manuscript; and all authors have read and approved the final manuscript.
Supported by PIP-CONICET 2021-2023 grant, No. 11220200100875CO; PICT-2020-Serie, No. A-00788; and “Florencio Fiorini Foundation” grants.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Julieta Trinks, MD, PhD, Professor, Instituto de Medicina Traslacional e Ingeniería Biomédica - Consejo Nacional de Investigaciones Científicas y Técnicas - Instituto Universitario del Hospital Italiano - Hospital Italiano de Buenos Aires, Potosí 4240, Ciudad Autónoma de Buenos Aires C1199ACL, Argentina. julieta.trinks@hospitalitaliano.org.ar
Received: December 27, 2023
Peer-review started: December 27, 2023
First decision: January 27, 2024
Revised: February 19, 2024
Accepted: March 25, 2024
Article in press: March 25, 2024
Published online: April 14, 2024
Processing time: 107 Days and 15.7 Hours
Core Tip

Core Tip: Identifying patients with metabolic dysfunction-associated steatotic liver disease (MASLD) at higher risk for adverse outcomes is still a crucial clinical challenge. Novel and non-invasive screening, monitoring, and risk stratification methods are urgently needed. With this aim, omics technologies have revolutionized the process of MASLD biomarker discovery. Although many omics-based biomarkers were identified over the past decades, their translation into clinically useful tests that can guide management decisions has proven more difficult than expected. This review presents an overview of this area’s current state, the conceivable opportunities and challenges of omics-based laboratory diagnostics, and a roadmap for improving MASLD biomarker research.